⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OPK News
Opko Health Inc.
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
globenewswire.com
ENTX
OPK
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
globenewswire.com
OPK
Starting Tomorrow! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy’s 2026 New York CISO Summit. Be a Part of It. Register Now.
globenewswire.com
MSFT
PFE
BAC
CVS
FMS
OPK
VERA
CMCSA
LH
Tetraspecific Antibodies Clinical Pipeline Market research 2026: Development Technologies, Therapeutic Approaches & Market Opportunity Insight to 2032
globenewswire.com
OPK
IPHA
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
globenewswire.com
OPK
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
globenewswire.com
OPK
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
globenewswire.com
OPK
Form 8-K
sec.gov
OPK
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
globenewswire.com
OPK
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
globenewswire.com
OPK